EB5 Capital Investor Obtains First Permanent Green Card Approval in Nashville Virgin Hotel (JF23) Project
WASHINGTON, May 21, 2025 (GLOBE NEWSWIRE) -- EB5 Capital is pleased to announce the first I-829 petition approval for an investor in its Nashville Virgin Hotel (JF23) project. The United States Citizenship and Immigration Services (USCIS) issues approval of the removal of conditions of residency for EB-5 investors who have completed their conditional residency period and have demonstrated that their investment has resulted in the creation of at least ten full-time jobs. I-829 approvals permit EB-5 investors to be lawful permanent residents of the United States. The approved petition was filed in April 2023 and was pending for 24.6 months.
'Securing an I-829 approval is a major milestone in the EB-5 immigration process,' said Nhat Huynh, Vice President of Investor Relations at EB5 Capital. 'We look forward to more investors getting approved soon.'
Nashville Virgin Hotel (JF23) is a 260-room luxury hotel situated in Nashville, Tennessee's famed Music Row District. The hotel is operated by Virgin Hotels, the lifestyle hotel brand by Virgin Group founder Sir Richard Branson. The project was completed in 2020 and generated over 1,500 jobs for the local economy.
To date, EB5 Capital has raised investor funds across over 45 EB-5 projects throughout the United States. JF23 is EB5 Capital's 20th project which has reached the permanent green card stage for investors going through the EB-5 immigration process. Now that the first petition has been approved, additional I-829 petition adjudications for this project are expected in the coming months.EB5 Capital provides qualified foreign investors with opportunities to invest in job-creating commercial real estate projects under the United States Immigrant Investor Program (EB-5 Visa Program). Headquartered in Washington, D.C., EB5 Capital's distinguished track record and leadership in the industry has attracted investors from over 75 countries. As one of the oldest and most active Regional Center operators in the country, the firm has raised over $1.4 billion of foreign capital across approximately 45 EB-5 projects. 100% of our investors' funds are protected by the Federal Deposit Insurance Corporation (FDIC) insurance prior to their deployment into our projects. Please visit www.eb5capital.com for more information.
Contact: Katherine WillisDirector, Marketing & Communicationsmedia@eb5capital.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
34 minutes ago
- Business Upturn
Alembic Pharma shares dip over 2% after USFDA issues 4 observations for Panelav facility
By Aman Shukla Published on June 2, 2025, 10:25 IST Shares of Alembic Pharmaceuticals fell over 2% on Monday following news that the United States Food and Drug Administration (USFDA) issued four observations after inspecting the company's API-I & II facility at Panelav, Gujarat. As of 10:22 AM, the shares were trading 1.88% lower at Rs 998.90. The unannounced, routine cGMP (current Good Manufacturing Practices) inspection was conducted between May 26 and May 31, 2025. At the conclusion of the inspection, the USFDA issued a Form 483 outlining four observations. Importantly, Alembic confirmed that none of the observations relate to data integrity — a key concern for regulators and investors. The company stated that it will submit a comprehensive response to the USFDA within the required timeframe. Management emphasized that the issues raised are 'addressable' and reiterated its commitment to maintaining high standards of quality and regulatory compliance. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
34 minutes ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
5 hours ago
- Yahoo
L&I assists thousands with unemployment compensation claims
Jun. 1—WILKES-BARRE — Now in its third year, the Pennsylvania Department of Labor and Industry's (L&I) UC Connect program continues to provide essential, in-person assistance to Pennsylvanians looking for help navigating the Unemployment Compensation (UC) system. Since its launch in May 2022, UC Connect has helped more than 106,000 Pennsylvanians resolve claims, navigate eligibility issues, and connect to community-based resources, helping more than 700 people in April 2025 alone. Offered at PA CareerLink locations statewide, UC Connect appointments are tailored to claimants who lack reliable internet, are unfamiliar with digital systems, or need language support. With sustained demand for in-person help, L&I has embedded UC Connect into its long-term customer service model. "As UC Connect enters its third year, it remains a necessary and effective tool for delivering unemployment services equitably," said L&I Secretary Nancy A. Walker. "In-person support ensures that no Pennsylvanian is left out of the system simply because they don't have access to broadband or need help understanding the process. L&I has expanded UC Connect's services and took the initiative statewide, and it's clear that our efforts are making a difference in delivering faster, better service for Pennsylvanians." After initially launched as a pilot program in 2022, UC Connect was made a permanent service through bipartisan investments in the 2023 — 24 budget, enabling L&I to hire more than 380 UC interviewers to expand service delivery across Pennsylvania. Unemployment Compensation system update The Department first eliminated a backlog of 40,000 claims from the pandemic era — each requiring case-by-case review — within seven months. The Department then shifted focus to scaling up staff, reducing wait times, and improving access for all Pennsylvanians. Key service highlights from April 2025 include: —Average call wait time was reduced to 18 minutes and 56 seconds. —5,321 live chat sessions were completed—an increase from the same time last year —44,077 new UC claims were filed —$157 million in UC benefits was paid to 99,518 individuals —86,616 helpline calls were answered —13,965 email inquiries were processed —709 individuals received in-person assistance through UC Connect Since the beginning of 2025, L&I has paid out $784 million in UC benefits to more than 483,000 individuals, responded to 361,258 helpline calls, and provided 3,112 UC Connect appointments. Risk-limiting audit of 2025 primary election begins The Department of State this week began Pennsylvania's statewide risk-limiting election audit (RLA) of the May 20 primary. "This is our sixth statewide risk-limiting audit since the 2022 general election," Secretary of the Commonwealth Al Schmidt said. "RLAs are proven to be the highest standard of comprehensive election audits because the RLA process provides a statistically sound, scientific method for confirming, with a high degree of confidence, that the reported outcome of the audited election is accurate." Schmidt said 10 Department employees took turns rolling 10-sided dice to deliver the random 20-digit "seed number," which is used to determine which batches of ballots counties will audit over the next several days. A random-selection drawing on May 23, resulted in the selection of the contest for the Republican nomination for Judge of Commonwealth Court for this RLA. During the audit, county officials will hand-tally the randomly selected ballot batches, then compare those vote counts to the original machine counts for the selected race. Known as a "batch comparison" type of RLA, this pre-certification audit can confirm whether counties accurately tabulated paper ballots so that a full hand count would produce the same reported outcome. The RLA will be carried out in addition to the 2% statutorily required review that counties must perform after each primary and general election in Pennsylvania. For that review, county officials are required to conduct a statistical recount of a random sample of at least 2% of all ballots cast, or 2,000 ballots, whichever is fewer. Counties must complete the RLA by June 5, and they must certify all election results to Schmidt by June 9. Fetterman joins push to return stolen art to Holocaust survivors U.S. Sen. John Fetterman, D-Braddock, is pushing legislation to help survivors of the Holocaust and their families reclaim tens of thousands of pieces of artwork stripped from them by the Nazis. The bill, sponsored by Fetterman and a bipartisan group of lawmakers, attempts to smooth the legal process for these survivors or their heirs as they petition the courts for return of the art, according to a news release. Though Congress passed a bill with the same aim nearly a decade ago, some museums, institutions and governments have stonewalled and battled families in their reclamation efforts, Fetterman's office said. "Some 80 years after the Holocaust, we have a moral responsibility to do right by the victims of these atrocities and their families," Fetterman said in a statement. The proposal extends the original Holocaust Expropriated Art Recovery Act, which is set to expire at the end of 2026. Recognizing the difficulty of tracking down artwork stolen during the Holocaust, Congress in 2016 passed the act to give families six years to file a legal claim for a piece after they've located it. The new bill backed by Fetterman also seeks to make sure families' court claims get fair consideration on their merits rather than being dismissed over technicalities, the release stated. During the Holocaust, Nazi Germany seized hundreds of thousands of pieces of artwork from Jewish people. While the U.S. and other allied nations have tried to restore these valuables to their rightful owners, more than 100,000 pieces still have not been given back, according to Fetterman's office. Fetterman is co-sponsoring the bill introduced by U.S. Sens. John Cornyn, R-Texas, and Richard Blumenthal, D-Connecticut. DCNR: Free menstrual products available in 68 state parks Department of Conservation and Natural Resources (DCNR) Secretary Cindy Adams Dunn this week was joined by First Lady Lori Shapiro and members of the Governor's Advisory Commission on Next Generation Engagement to announce a new initiative that makes free menstrual products available in 68 state parks across Pennsylvania. The products are now stocked in park offices, visitor centers, and environmental educational centers at participating parks, offering a convenient and essential resource for visitors. Signage in English and Spanish helps park-goers locate where products are available. This effort is part of the Shapiro Administration's broader work to make public spaces across the Commonwealth more accessible and supportive for all. The announcement coincides with Menstrual Hygiene Day — highlighting the importance of addressing period poverty through public policy and access. "I've been so inspired by all the young women I've met who are making their voices heard and starting conversations on period poverty — talking so comfortably about something that, for so long, has been a taboo subject," said First Lady Shapiro. "Thanks to them speaking up, Pennsylvania has taken some major steps to ensure more women have access to basic hygiene supplies throughout the day. I want everyone to be able to enjoy their time outdoors, and DCNR's work to get free menstrual products in the bathrooms and visitor offices of our state parks is critical to making our outdoor spaces welcoming to everyone." "No one should have to cut an outdoor adventure short because of their period — DCNR has you covered," said Secretary Dunn. "We are committed to creating inclusive, welcoming outdoor spaces — and that means meeting people's basic needs without stigma or barriers." DCNR will evaluate the program's success and expand it to additional park locations in the future. Reach Bill O'Boyle at 570-991-6118 or on Twitter @TLBillOBoyle.
